tag:blogger.com,1999:blog-55385390295440173142009-07-09T16:35:27.722-07:00Latest News About Clinical Research . Clinical Trials Online CourseAbout me:http://www.blogger.com/profile/02612823039946492603noreply@blogger.comBlogger1125tag:blogger.com,1999:blog-5538539029544017314.post-42863092531838874542008-05-06T01:59:00.000-07:002008-05-06T02:04:52.800-07:00Toclizumab is a humanized anti-<a href="http://en.wikipedia.org/wiki/Interleukin-6_receptor" title="Interleukin-6 receptor" rel="wikipedia" target="_blank" class="zem_slink">interleukin 6 receptor</a> agent that blocks the action of the inflammatory cytokine. The drug is in <a href="http://en.wikipedia.org/wiki/Clinical_trial" title="Clinical trial" rel="wikipedia" target="_blank" class="zem_slink">phase III trials</a> worldwide, and is licensed in Japan as an orphan drug for treatment of Castleman's disease.<br /><br />In a phase II European trial of toclizumab, 61% of patients had an ACR20 response, 43% had an ACR50 response, and 16% had an ACR70 response at a dose of 8 mg/kg.<br /><br /><center><object height="355" width="425"><param name="movie" value="http://www.youtube.com/v/b1mBX57JTaQ&amp;hl=en"><param name="wmode" value="transparent"><embed src="http://www.youtube.com/v/b1mBX57JTaQ&amp;hl=en" type="application/x-shockwave-flash" wmode="transparent" height="355" width="425"></embed></object></center><div class="blogger-post-footer"><img width='1' height='1' src='https://blogger.googleusercontent.com/tracker/5538539029544017314-4286309253183887454?l=clinicaltrialsweb.blogspot.com'/></div>About me:http://www.blogger.com/profile/02612823039946492603noreply@blogger.com0